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Chemokines are small chemotactic molecules that play key roles in physiological and 
pathological conditions. Upon signaling via their specific receptors, chemokines regulate 
tissue mobilization and trafficking of a wide array of immune cells, including natural killer 
(NK) cells. Current research is focused on analyzing changes in chemokine/chemokine 
receptor expression during various diseases to interfere with pathological trafficking of 
cells or to recruit selected cell types to specific tissues. NK cells are a heterogeneous lym-
phocyte population comprising several subsets endowed with distinct functional proper-
ties and mainly representing distinct stages of a linear development process. Because of 
their different functional potential, the type of subset that accumulates in a tissue drives 
the final outcome of NK cell-regulated immune response, leading to either protection 
or pathology. Correspondingly, chemokine receptors, including CXCR4, CXCR3, and 
CX3CR1, are differentially expressed by NK cell subsets, and their expression levels can 
be modulated during NK cell activation. At first, this review will summarize the current 
knowledge on the contribution of chemokines to the localization and generation of NK 
cell subsets in homeostasis. How an inappropriate chemotactic response can lead to 
pathology and how chemokine targeting can therapeutically affect tissue recruitment/
localization of distinct NK cell subsets will also be discussed.
Keywords: chemokine receptors, CXCR4, CXCR3, nK cell subsets, multiple sclerosis, multiple myeloma, cross-
inhibition, migration
inTRODUCTiOn
Natural killer (NK) cells are innate lymphocytes that play a key role in the immune response to 
tumors and infections through their ability to kill transformed or infected cells and to produce 
immunoregulatory cytokines and chemokines. Activation of NK cell effector functions can be 
achieved through a complex integration of inhibitory and activation signals provided by membrane 
expressed receptors and/or through cytokine stimulation (1).
Natural killer cells are widely distributed into different tissues such as the bone marrow (BM), 
liver, thymus, lymph node, and uterus, thus contributing to immune surveillance in homeostasis, 
and can be further recruited into tissues in pathological conditions (2, 3). While tissue-resident 
NK cells have been identified in uterus, liver, and skin, conventional NK cells continuously traffic 
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FigURe 1 | Differential chemoattractant receptor expression by nK cell subsets in human and mouse.
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and localize into tissue through a combination of stimuli able to 
promote their mobilization from storage compartments to blood 
circulation and their entry and retention into tissue (4–6).
Chemokines are a family of more than 50 small proteins, 
mostly secreted, that accomplish their function by interacting 
with heterotrimeric G protein-coupled receptors (GPCR). 
Chemokine binding promotes a conformational change in the 
receptor, triggering intracellular signals that drive cell polariza-
tion, migration, and adhesion, thus resulting in the induction 
of leukocyte trafficking and homing (3). Besides leukocyte 
chemotaxis, chemokines can affect a number of other leukocyte 
functions and are recognized as important regulators of the 
immune response (3). Chemokines may be grouped according 
to their modality of expression and function, as inflammatory or 
homeostatic (7).
CHeMOKine ReCePTOR eXPReSSiOn 
On nK CeLL SUBSeTS
A number of evidence indicates that the differential functional 
properties underlying NK cell-mediated protective effect in 
pathological conditions can be attributed to distinct NK cell pop-
ulations endowed with distinct expression patterns of activating 
and inhibitory as well as homing receptors. Two major subsets 
of mature NK cells were identified in human peripheral blood 
with respect to the neural cell adhesion molecule CD56 and the 
low affinity receptor for IgG, FcγRIII CD16. The CD56highCD16low 
subset accounts for around 10% of circulating CD56+ NK cells 
and exerts immunomodulatory effects producing large amount 
of cytokines such as IFNγ in response to activation, whereas 
CD56lowCD16high cells are the major cytotoxic population 
representing the majority of circulating CD56+ NK cells [for a 
review on human NK subsets, see Ref. (8)]. Although the exact 
relationship between these NK cell subsets still remains unclear, 
evidence suggest that CD56low NK cells originate from CD56high 
NK cells (9–12).
Natural killer cell subsets display a differential pattern of 
chemokine receptor expression (Figure  1). CD56high NK cells 
are targeted to lymph nodes via CCR7, preferentially express 
CXCR3 and have higher CXCR4 expression levels as compared 
with CD56low cells. CD56low NK cells uniquely express CXCR1, 
ChemR23, and CX3CR1 (Figure 1) (see Table 1 for a list of ligands 
of chemoattractant receptors expressed by human and mouse 
NK cell subsets) (13–18). More recently, a new CD56lowCD16low 
subset has been identified and found to be prominent in the BM 
of healthy pediatric donors, to display potent killing and IFNγ 
producing capacity, and to expresses higher levels of CXCR4 and 
TABLe 1 | Chemokine receptor expression by nK cells and their 
respective ligands.
Chemokine receptor Chemokine ligand
CCR1 CCL3/MIP-1α, CCL5/RANTES, CCL7/MCP-3, 
CCL9/CCL10/MIP-1γ, CCL14/HCC-1, CCL15/
HCC-2, CCL16/HCC-4, CCL23/MPIF-1
CCR2 CCL2/MCP-1, CCL7/MCP-3, CCL12,  
CCL13/MCP-4, CCL16/HCC-4
CCR5 CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, 
CCL8/MCP-2, CCL14/HCC-1
CCR7 CCL19/MIP-3β/ELC, CCL21/SLC
CXCR1 CXCL8/IL-8
CXCR3 CXCL9/Mig, CXCL10/IP-10, CXCL11/I-TAC
CXCR4 CXCL12/SDF-1
CXCR6 CXCL16/SR-PSOX
CX3CR1 CX3CL1/fractalkine
Chemoattractant receptors Ligand
S1P5 S1P
ChemR23, CCRL2 Chemerin
The previous chemokine name follows the one currently used.
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CXCR3 compared with the other subsets (17). In addition, other 
subsets related to NK cell maturation, including cells coexpress-
ing CD57, a member of the glucuronyl-transferase gene family 
or the L-selectin within the CD56low NK cells are currently active 
field of investigation (19–21).
Mouse NK cells do not express the murine ortholog of CD56, 
but four different developmentally related subsets have been 
identified on the basis of the expression levels of the integrin 
chain CD11b and of a member of the TNF receptor superfamily, 
CD27: CD11blowCD27low, CD11blowCD27high, CD11bhighCD27high, 
and CD11bhighCD27low (22, 23). The inhibitory receptor KLRG1 
is acquired by the most mature subset and identifies NK cells with 
reduced effector functions (24). KLRG1 coexpression with the 
chemokine receptor CX3CR1 identifies an even later maturation 
stage with unique functional properties (25). Likewise, other NK 
cell subsets can be defined according to the expression of selected 
chemokine receptors: the prevalent expression of CXCR3 on 
CD56high was related to expression of the receptor on mouse 
CD27high NK cells and more in general to stronger proliferative 
and cytokine production capacity (26, 27). In addition, CXCR6 
was shown to identify an NK cell population resident in liver 
displaying in humans a CD56highCD16−CD57− phenotype, 
and expressing TRAIL in diseased liver, and in the mouse a 
DX5−TRAIL+ phenotype (28, 29).
CHeMOKine ReCePTOR inTeRPLAY FOR 
eFFiCienT MigRATiOn in COMPLeX 
CHeMOTACTiC enviROnMenT
Leukocytes express multiple chemokine receptors not only to 
robustly and promptly infiltrate tissues upon activation but also 
to navigate through the network provided by multiple competing 
chemotactic gradients perceived into tissue. Indeed, discrimina-
tion of a dominant chemoattractant is required to localize in the 
correct microenvironment and/or to make a decision on whether 
to stay or to leave a tissue (30, 31). The ability to preferentially 
respond to selected chemoattractants was at first demonstrated in 
neutrophils and was postulated to require heterologous receptor 
desensitization that is the transinhibition of a chemokine recep-
tor resulting from the activation of second messenger-dependent 
kinases by a dominant chemoattractant receptor (32–34). In this 
regard, triggering CXCR2 by KC was shown to be required for 
neutrophil egress from the BM not only by promoting neutrophil 
migration but also by inhibiting CXCR4-mediated BM retention 
(35). Afterward, our group showed that CXCR4 heterologous 
desensitization is also associated with NK cell egress from BM into 
circulation (36, 37). On the other hand, the sphingophospholipid 
chemoattractant sphingosine-1-phosphate (S1P) promotes NK 
cell egress from BM under steady state without inducing CXCR4 
heterologous desensitization (38). CX3CL1, a ligand for CX3CR1 
constitutively expressed in BM, acts similarly on a small highly 
differentiated subset which poorly expresses CXCR4 (25,  39). 
While homeostatic chemokines may be sufficient for NK cell 
egress under steady state, heterologous receptor desensitization 
could be a mechanism to rapidly switch NK cell responsiveness 
promoted by inflammatory chemokines, to promptly facilitate 
BM NK cell availability in circulation.
Besides desensitization, CXCR4-mediated transinhibition 
can occur through other mechanisms, including receptor 
heterodimerization and G protein scavenging (40). In regard to 
heterodimerization, it is becoming increasingly clear that recep-
tor dimers are constitutively formed, and that ligand binding to 
one receptor can reorganize receptor complexes thus affecting 
different aspects of the associated chemokine receptor activity, 
including ligand affinity, the activated signaling cascades, and the 
receptor internalization (41–43). For example, CXCR3/CXCR4-
heterodimerization was shown to reduce the binding affinity of 
CXCR4 for its ligand (44).
Apart from the mechanism involved, cross-regulation pro-
moted by CXCR3 was shown to be relevant in several pathological 
conditions in mouse disease models. For example, O’Boyle and 
coworkers demonstrated CXCR4 and CCR5 inhibition on T cells 
by using a mimetic of CXCL10, a CXCR3 ligand. The use of this 
mimetic in a humanized mouse air-pouch model demonstrated 
reduced trafficking of T cells toward synovial fluids from patients 
with active rheumatoid arthritis, indicating that the triggering of 
a single chemokine receptor can control the immune response in 
chronic inflammatory conditions where CXCL12 is produced at 
high levels (45, 46). More recently, our observations in a mouse 
model of multiple myeloma led us to hypothesize that increased 
expression of CXCR3 ligands in the tumor BM microenviron-
ment constitutes a new mechanism to avoid tumor infiltration by 
NK cells: ligand-induced CXCR3 activation on KLRG1− NK cells 
resulted in cross-desensitization of CXCR4 that together with the 
coincident down-modulation of CXCL12 protein levels promotes 
NK cell egress from BM into blood circulation. The final outcome 
of this process is the reduction of the localization of this subset 
at the tumor site (39). On the other hand, when studying human 
plasmacytoid dendritic cells (pDC), a positive cooperative 
interaction was observed between the two receptors (47). This 
observation, together with a consistent adjacent expression of 
TABLe 2 | influence of dysregulation of chemokine receptor/ligand axes in pathologies on nK cell subsets.
nK cell 
subset
Chemokine-related 
alterations
Disease effects Reference
CD56low ↑CXCR4 Neuroblastoma Less recruitment to tumor site – tumor immune evasion (55)
↓CX3CR1
KLRG1− ↓CXCL12 Multiple myeloma Less recruitment to tumor site – tumor immune evasion (39)
↓CXCR3
↑CXCL9/10
NK cells ↑CXCR4 Multiple sclerosis Enhanced chemotaxis toward CXCL12 – neuroprotective role (69)
CD56high ↓CXCR4 Paroxysmal nocturnal hemoglobinuria Less secondary lymphoid tissue relocation (58)
CD56low ↓CXCR4 GATA2 deficiency Reduced chemotaxis toward CXCL12 (63)
NK cells ↑CXCR4 WHIM Enhanced chemotaxis toward CXCL12 (38, 64, 65)
CD27high ↑CXCL9/10 Cowpox virus infection Increased recruitment to lymph nodes (77)
Protection from infection
NK cells ↑CXCL10 HCV infection Less recruitment to liver – immune response dampening (81)
Truncated form
CD56low ↑CXCL9/10 Primary biliary cirrhosis Autologous cytotoxicity – tissue damage (82–85)
CD56high ↑CXCR3 Psoriatic skin Local inflammation – disease progression (86)
↑CXCL10
CD56high ↑CXCR3 ligands Periprosthetic osteolysis Local inflammation – immunoregulatory role (87)
↑ indicates up-modulation/increase frequency and ↓ indicates down-modulation/reduced frequency.
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CXCL12 with CXCR3 ligands in human tissues, led the authors 
to hypothesize that the cooperation between CXCR3 ligands and 
CXCL12 controls the tissue recruitment of pDCs.
Considering the highlighted importance of CXCR3/CXCR4 
interplay, hereafter we will document the critical role of CXCR3 
and of CXCR4 receptor/ligand axes in the regulation of NK cell-
mediated function in pathologies (summarized in Table 2).
CXCR4 ReCePTOR/LigAnD AXiS
CXCL12 displays a constitutive but restricted expression pattern 
in situ, with selective expression by CXCL12 abundant reticular 
(CAR) cells and osteoblasts in BM, by subpopulations of neuronal 
and endothelial cells in the brain, by dermal endothelial cells, and 
by invading trophoblast cells and lymph node high endothelial 
venules (48–54). Correspondingly, CXCR4/CXCL12 axis was 
reported to regulate NK cell functions in several physiological 
processes. It was shown that CXCL12 regulates the position-
ing in the BM of selected NK cell subsets at various stages of 
maturation; in addition, during pregnancy, human peripheral 
blood CD56highCD16− NK cells can be recruited by CXCL12 and 
migrate to the uterus (36, 48).
Considering the key role of CXCL12 in the localization of NK 
cells in BM, subversion of the CXCR4/CXCL12 axis has been 
hypothesized to represent a mechanism of immune evasion from 
NK-mediated immune surveillance in neuroblastoma and mul-
tiple myeloma (39, 55). TGF-β1 produced by neuroblastoma cell 
lines was shown to upregulate the surface expression of CXCR4 
and CXCR3 on both CD56high and CD56low NK cells, while it 
downregulated CX3CR1 in the CD56low subset. Increased CXCR3 
and reduced CX3CR1 expression was observed also in peripheral 
blood NK cells of stage 4 neuroblastoma patients, and it may rep-
resent an attempt to avoid NK cell cytolytic subset recruitment to 
the tumor site, while promoting the enrichment of immature and 
poorly cytotoxic CD56high subset in tumor leukocyte infiltrates 
(55, 56). Similarly, accumulation of CD56high NK cells was shown 
to occur in several tumors and may be related to the respon-
siveness of this subset to a combination of tissue-expressed 
chemokines: by analyzing the chemokine expression pattern 
of various normal solid tissues, Carrega and coworkers docu-
mented that some tissues are clearly oriented to recruit CD56high 
cells when CXCL12 is coexpressed with other chemokines (LN, 
colorectal, stomach, and liver tissues), while anatomic compart-
ments with the lowest proportion of CD56high within NK cells 
(lung and breast tissues) display a chemokine expression profile 
favoring CD56low NK cell recruitment (57). Similarly, decreased 
levels of CXCL12 in BM plasma samples from a cohort of patients 
with active multiple myeloma as compared with a premalignant 
stage support the hypothesis of a reduced NK cell surveillance 
based on reduced BM recruitment (39).
The key role of CXCR4 expression for NK cell homeostasis 
is also highlighted by genetic defects responsible for altered or 
lost CXCR4 function. For example, a more abundant proportion 
of circulating GPI−CD56high NK cells in paroxysmal nocturnal 
hemoglobinuria patients, a disease caused by dampened bio-
synthesis of glycosylphosphatidylinositol (GPI)-linked protein, 
was associated with reduced responsiveness of this population 
to the CXCR4 ligand CXCL12 (58, 59). In addition, deficiency 
of the transcription factor GATA2 is characterized by several 
hematological and non-hematological abnormalities among 
which NK cell cytopenia, with almost complete absence of 
circulating CD56high subset (60). Interestingly, CD56low NK cells 
display reduced CXCR4 surface expression levels and reduced 
chemotaxis to CXCL12 that was attributed decreased expression 
of filamin A and β-arrestin-1, two proteins regulating CXCR4 cell 
surface expression and endocytosis (61–63). On the other hand, 
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NK cells from patients affected by warts, hypogammaglobuline-
mia, infections, and myelokathexis (WHIM) syndrome display 
enhanced responsiveness to CXCL12 (38, 64, 65). Similarly, NK 
cells from mice displaying the most common mutation of the 
CXCR4 gene associated with WHIM syndrome show enhanced 
migration to CXCL12 that is linked to impaired CXCR4 desen-
sitization and internalization after CXCL12 stimulation. Possibly 
for this reason, NK cell distribution is altered, with CD11blow and 
CD11bhighCD27high NK cells accumulating in the BM.
Although CXCR4 mutation in WHIM syndrome was not 
associated with any NK cell-related disease, a selective defect of 
CXCR4 internalization after CXCL12 binding underlies a new 
rare immune deficiency documented in two cases of disseminated 
Mycobacterium avium infection, where a marked reduction in the 
number of circulating NK cells as well as neutrophils and B cells 
was observed (66).
An altered pattern of CXCL12 expression in brain has been 
reported in multiple sclerosis (67, 68), suggesting the involve-
ment of the CXCR4/CXCL12 axis in the leukocyte infiltration 
that characterizes this pathology. In this regard, while the inter-
ference with CXCR4/CXCL12 axis often leads to reduced NK 
cell protection in pathological conditions, Serrano-Pertierra and 
colleagues have found increased NK cell chemotaxis in response 
to CXCL12 in multiple sclerosis patients in the remitting phase 
and in clinically isolated syndrome patients with respect to 
relapsing multiple sclerosis patients and healthy controls. This 
finding has been associated with higher frequencies of NK cells 
expressing CXCR4 in the blood of the former patients’ cohorts 
(69). The enhanced NK cell migration in patients with a less 
active disease course supports the idea of a neuroprotective role 
for NK cells in multiple sclerosis (70). Unfortunately, NK cells 
have been studied as a whole, and the authors agree it would 
be of interest to analyze NK cell subsets, also considering that 
the size of the circulating CD56high NK cell pool is significantly 
associated with clinical remissions and that expansion of 
this population is associated with amelioration of diseases in 
response to therapy (71–75).
CXCR3 ReCePTOR/LigAnD AXeS
CXCR3 ligands are expressed at low levels in homeostatic condi-
tions, but their expression can be upregulated in both the hemat-
opoietic and non-hematopoietic compartment by IFN-γ and some 
related cytokines. Several studies in humans and mice reveal that 
NK cells can promote adaptive immune response by modulating 
dendritic cell (DC) function and T helper cell polarization (76). 
This important function is linked to CXCR3-mediated NK cell 
recruitment into draining lymph node in several conditions. In 
mouse, in accordance with higher and preferential expression 
levels of CXCR3, the NK cell population mostly affected by 
CXCR3 function is the CD27high subset that colonizes draining 
LN following DC vaccination, cowpox virus infection, and dur-
ing tumor growth (77, 78). Several studies have correlated high 
numbers of tumor-infiltrating NK cells with a good prognosis for 
cancer patients and with tumor cell clearance in mouse tumor 
models. This has been related to the IFN-γ promotion of CXCL9 
and CXCL10 production by tumor-infiltrating leukocytes, 
leading to the CXCR3-mediated recruitment of mouse CD27high 
NK cells, the population of NK cells with the higher functional 
potential (79).
The influence of CXCR3–CXCL10 axis on NK cell function 
was documented also in human pathologies. Upregulation of 
CXCR3 ligands in multiple myeloma patients with active disease 
corresponded to marked down-modulation of CXCR3 expres-
sion levels by BM NK cells, an event that was linked to reduction 
of NK cell localization in the BM in multiple myeloma-bearing 
mice. In addition, high CXCL9 and CXCL10 serum levels were 
associated with several established prognostic parameters and 
predicted poor overall survival (39, 80).
CXCL10/CXCR3 axis is involved in hepatic trafficking of 
NK cells, which also represent an important component of 
the intrahepatic lymphocyte pool and has been implicated in 
the pathogenesis of chronic hepatitis C virus (HCV) infection. The 
CD56highCXCR3+ NK cells display the strongest activity against 
hepatic stellate cells, thus regulating liver fibrosis. Although 
expanded in HCV-infected patients, the CD56highCXCR3+ NK 
cell subset display impaired functions that may be linked to 
HCV-associated liver fibrosis (27). Elevated levels of CXCL10 
were found in serum of patients and were predictive of the failure 
to respond to HCV therapy. Nevertheless, in a recent study, it 
has been reported that CXCL10 in the serum of HCV patients 
may not be biologically active, representing a truncated form 
that can bind to CXCR3 without signaling. In the presence of 
higher levels of this CXCL10 antagonist, NK cells might fail 
to migrate to the infected liver and accumulate instead in the 
peripheral circulation (81).
Chemokines play an important role in destruction of the 
biliary tract (82) by recruiting cells of the immune system, 
including NK cells. As such, liver NK cells have been reported 
to express the chemokine receptors CX3CR1 and CXCR3 (83). 
Among the principal chemokines involved in hepatic immune 
cell migration, CXCL9 and CXCL10 are both increased in serum 
of patients with primary biliary cirrhosis (PBC) compared with 
normal individuals and are preferentially expressed in the portal 
areas, corresponding to CD56lowCD16+ NK cell liver infiltration 
increased numbers of CD56+ cells located around the destroyed 
small bile ducts (84, 85).
Several reports documented that CD56high NK cells also infil-
trate inflamed skin in a CXCL10-dependent fashion. Ottaviani 
et al. have shown that psoriatic keratinocytes display an enhanced 
capacity to produce CXCL10, and CD56highCD16− NK cells showed 
an upregulation of CXCR3, in comparison to CD56lowCD16+ NK 
cells (86). CD56highCXCR3+CCR5+ cells produced IFNγ after IL2 
stimulation that in turn potentiates activation of keratinocytes 
and upregulates HLA class-I. These findings would suggest that 
CD56+ NK cells are recruited in psoriatic skin through a mecha-
nism involving the CXCL10/CXCR3 axes and that, once in the 
skin, they may contribute to the disease progression by inducing 
local inflammation and amplifying T cell autoimmune reactivity.
Similar to psoriatic skin-infiltrating NK cells, NK cells in the 
synovial tissue of osteoarthritis patients are CCR5+CXCR3+. 
High levels of CXCR3 and CCR5 ligands present in synovial 
fluids after revision surgery, as well as evidence of particle-
induced chemokine production by macrophages (87), suggest a 
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mechanism for recruitment of a subset functionally correspond-
ing to CD56highCD16− NK cells during periprosthetic osteolysis. 
The majority of synovial tissue-infiltrating NK cells express a 
combination of surface receptors consistent with a non-cytotoxic 
phenotype similar to blood.
COnCLUSiOn
The correct localization of NK cells into tissues has a fundamental 
role in several aspects of NK cell-mediated immune responses 
in vivo. Thus, identification of the key mediators regulating NK 
cell tissue recruitment is a critical step in the optimization of 
current cancer immunotherapy protocols or in the treatment of 
inflammatory diseases.
When NK cell tissue accumulation is important, the thera-
peutic enhancement of expression of selected chemokines that 
attract NK cells specifically is a valuable approach to increase 
the penetration and/or local activation and differentiation of 
NK cells at the tumor site. Ectopic expression of chemokines/
chemoattractants known to preferentially attract effector 
lymphocytes, including CXCR3 ligands as well as CX3CL1 and 
chemerin, was shown to positively affect the antitumor nature 
of tumor-infiltrating lymphocytes with a large proportion of NK 
cells (88–91). Nevertheless, high concentrations of attracting 
chemokines do not always imply increased NK cell migration, 
as shown by Halama and coworkers in colorectal cancer tissue 
where NKp46+ NK cells are poorly infiltrated, despite high local 
chemokine levels (92).
An alternative and highly novel strategy to improve NK 
cell migration to target tissues is to promote or optimize the 
expression of chemoattractant receptors on NK cells to be used 
for adoptive immunotherapy. The expression of chemokine 
receptors and the corresponding NK cell chemotactic response 
can be modulated upon cytokine-mediated activation thus sug-
gesting that they may better home to tumor sites where their 
corresponding ligands are expressed (93–96). In addition, NK 
cells ex vivo engineered to express chemokine receptors by gene 
transfer or by trogocytosis are under investigation for their better 
tissue homing and function (97–101). Conversely, a number of 
new clinical trials for immune-mediated diseases based on the 
use of chemokine receptor antagonists are ongoing and will help 
to understand the therapeutic potential of these important targets 
for NK cell-promoted pathologies (102). Finally, the emerging 
role of chemoattractant receptor interplay in the regulation of 
immune cell response may also lead to the discovery of molecules 
able to block chemokine receptor cross-inhibition thus allowing 
to unleash the full chemotactic potential of important NK cell 
receptors, such as CXCR4.
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